Last reviewed · How we verify

Marezine — Competitive Intelligence Brief

Marezine (CYCLIZINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cyclizine. Area: Immunology.

marketed cyclizine Histamine H1 receptor Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Marezine (CYCLIZINE) — GSK.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Marezine TARGET CYCLIZINE GSK marketed cyclizine Histamine H1 receptor 1982-01-01
Lastacaft ALCAFTADINE AbbVie marketed Histamine-1 Receptor Antagonist [EPC] Histamine H1 receptor 2010-01-01
Xyzal LEVOCETIRIZINE Sanofi marketed Histamine-1 Receptor Antagonist Histamine H1 receptor 2007-01-01
Elestat EPINASTINE AbbVie marketed Adrenergic Receptor Agonist Histamine H1 receptor 2003-01-01
Rupax RUPATADINE Teikoku Seiyaku marketed rupatadine Histamine H1 receptor 2001-01-01
Zaditor KETOTIFEN marketed Histamine-1 Receptor Inhibitor Histamine H1 receptor 1999-01-01
Mizollen MIZOLASTINE Sanofi marketed mizolastine Histamine H1 receptor 1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cyclizine class)

  1. GSK · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Marezine — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclizine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: